-
Mashup Score: 1Precision oncology company Sentinal4D completes pre-seed funding round and launches to the public - 13 day(s) ago
Precision oncology company Sentinal4D completes pre-seed funding round and launches to the public
Source: www.icr.ac.ukCategories: General Medicine News, Oncologists1Tweet
-
Mashup Score: 4Overcoming recurrence – how research is bringing new hope for breast cancer patients - 14 day(s) ago
Overcoming recurrence – how research is bringing new hope for breast cancer patients
Source: www.icr.ac.ukCategories: General Medicine News, Oncologists1Tweet-
Our scientists have found a way to predict breast cancer recurrence even years ahead, providing plenty of opportunity to intervene. They’re also developing multiple innovative treatments that could prevent recurrence from occurring at all. Learn more ➡️ https://t.co/ioFlsjIiSa https://t.co/j5gYqvEyso
-
-
Mashup Score: 9Scientific achievements of 2024 - 16 day(s) ago
Scientific achievements of 2024
Source: www.icr.ac.ukCategories: General Medicine News, Oncologists1Tweet-
As the end of 2⃣0⃣2⃣4⃣ approaches, we look back at some of our research highlights from recent months ✨ As ever, our achievements cover a range of cancer types and represent the full spectrum of research, from lab bench to clinic bedside. Our top ten⬇️ https://t.co/W771p4weCK https://t.co/zjxvSpPLFI
-
-
Mashup Score: 8“Hearing the words ‘you have cancer’ blew me away, but I was determined to beat it” – Natasha’s story - 17 day(s) ago
When Natasha, 51, was told she had stage 2 DCIS breast cancer in November 2018, she became the third woman in her family to receive such a diagnosis. Now nearly six years on and cancer free, Natasha shares her story.
Source: www.icr.ac.ukCategories: General Medicine News, Oncologists1Tweet-
Natasha was diagnosed with breast cancer in 2018. But thanks to successful treatment, she is back to doing life. This Christmas, give the gift of research to help women like Natasha live longer, better lives. Read her inspirational story here ❤️ https://t.co/TY1uW03kgm https://t.co/poJLKsMli4
-
-
Mashup Score: 3
One year of treatment with the targeted drug olaparib improves long-term survival in women with high-risk, early-stage breast cancer with mutations in BRCA1 or BRCA2 genes, new results from a major clinical trial show.
Source: www.icr.ac.ukCategories: General Medicine News, Oncologists1Tweet-
📰 NEWS: Latest findings from the OlympiA clinical trial show prolonged benefit of olaparib against early-stage #BreastCancer with inherited BRCA mutations. The research, involving ICR scientists, is presented today at @SABCSSanAntonio Read more ⬇️ https://t.co/ctFwFYATZo https://t.co/ArhGUSOvs4
-
-
Mashup Score: 5
Scientists have developed a machine learning tool that can predict how an aggressive type of breast cancer will respond to treatment, and when it will return.
Source: www.icr.ac.ukCategories: General Medicine News, Oncologists1Tweet-
Our scientists have developed a machine learning tool that could help predict outcomes, tailor treatment, and identify new drug targets for #LobularBreastCancer Find out more ⬇️ https://t.co/R0ofPdKwYX
-
-
Mashup Score: 7
Natalie Pearce, 52, was diagnosed with stage 3c ovarian cancer in November 2012. She subsequently discovered she carries the BRCA1 gene mutation, putting her at a higher risk of developing various cancers. Following surgery and treatment, Natalie has been cancer free since April 2013.
Source: www.icr.ac.ukCategories: General Medicine News, Oncologists1Tweet-
“Cancer research is so important. I wouldn’t be here without it” Natalie was diagnosed with #OvarianCancer at the age of 40. Now, 12 years on, she feels incredibly lucky to be here ♥️ Give the gift of research to help women live longer, better lives. https://t.co/YajVkHMwAC https://t.co/X8B0f96l2t
-
-
Mashup Score: 19
Scientists have worked out a way of predicting how long a prostate cancer patient will continue to respond to the PARP inhibitor drug, olaparib, according to new research published in the journal Cancer Cell.
Source: www.icr.ac.ukCategories: General Medicine News, Oncologists1Tweet-
📰 BREAKING: Scientists have worked out a way of predicting how long a #ProstateCancer patient will continue to respond to olaparib. The team used a simple blood test to detect the presence of changes that affect how well the drug can act on cancer ⬇️ https://t.co/XsE1bSwaUa
-
-
Mashup Score: 14
Help women with ovarian and breast cancer live longer and better lives by supporting the Institute of Cancer Research. Donate today.
Source: www.icr.ac.ukCategories: General Medicine News, Oncologists1Tweet-
Today, we launch our appeal to help more women with ovarian and breast cancer live longer, better lives ♥️ Support our lifesaving research to find new treatments and defeat cancer. This Christmas, donate and make an impact that can last a lifetime. https://t.co/Rqw813wmfY https://t.co/mt87Xk7xFb
-
-
Mashup Score: 9
Jesse was two years old when he was diagnosed with B-cell acute lymphoblastic leukaemia, a type of blood and bone marrow cancer, in November 2023. Now, a year since his diagnosis and thankfully in remission, Jesse’s mum, Polly, shares their story to mark World Children’s Day.
Source: www.icr.ac.ukCategories: General Medicine News, Oncologists1Tweet-
“It’s great to see Jesse getting stronger every day” Jesse was diagnosed with B-cell acute lymphoblastic #Leukaemia last November at the age of two. Now, a year on, to celebrate his remission, his mum, @pollyosborn shares his story 💙 https://t.co/v8bPmWZvrd #WorldChildrensDay https://t.co/6tj1Wu3mBY
-
The company is built on years of data and expertise developed in the lab of ICR's Professor Chris Bakal, a leading expert in cell shape in cancer, and includes former ICR PhD Student Matt de Vries and is being led by Dr Georgia Mitsi. Read more here ⬇️ https://t.co/KAshvRUaqo https://t.co/7wuuf47rqF